NL-OMON35646已完成不适用
RAAS-blockade in type II diabetes: added effects of a low sodium diet and diuretics. - DiNaMO
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age between 18-70 years
- •Type II diabetes
- •Albuminuria > 30 mg/24h
- •Stable 24h creatinine clearance >30 ml/min/1,73 m2
排除标准
- •Contraindication for the use of lisinopril or hydrochlorothiazide
- •Type I diabetes
- •Myocardial infarction or stroke within 3 month prior to the research
- •Kidneydisease unrelated to diabetes or hypertension
- •Proteinuria >3 gr/24h
- •Hypertension unresponsive to therapy during run-in period
- •Inabilty for informed consent
- •Incompliance to diet or studymedication
- •Inaccordance with inclusioncriteria
研究者
相似试验
已完成
不适用
RAAS-blockade in type II diabetes: added effects of dietary sodum restriction and diuretics.Diabetes Mellitus, proteinuria, albuminuria, hypertension, kidney disease, dietary sodium, RAAS-blockadeNL-OMON24944niversity Medical Center Groningen (UMCG)55
招募中
不适用
Effects of a SGLT2 Inhibitor in type 2 Diabetes Mellitustype 2 Diabetes MellitusJPRN-UMIN000017461ephrology, endocrinology and vascular medicine at Tohoku University Hospital60
进行中（未招募）
不适用
iraglutide Effect and Action in Diabetes (LEAD-2): Effect on glycaemic control after once daily administration of liraglutide in combination with metformin versus metformin monotherapy versus metformin and glimepiride combination therapy in subjects with type 2 diabetes. A six-month double-blind, double-dummy, randomised, active control, parallel-group, multi-centre, multi-national trial with an 18 months trial extension periodMedDRA version: 8,0Level: PTClassification code 10012601Diabetes MellitusEUCTR2005-003417-32-BEovo Nordisk A/S1,865
进行中（未招募）
1 期
iraglutide Effect and Action in Diabetes (LEAD-2): Effect on glycaemic control after once daily administration of liraglutide in combination with metformin versus metformin monotherapy versus metformin and glimepiride combination therapy in subjects with type 2 diabetes. A six-month double-blind, double-dummy, randomised, active control, parallel-group, multi-centre, multi-national trial with an 18 months trial extension periodMedDRA version: 8,0 Level: PT Classification code 10012601Diabetes MellitusEUCTR2005-003417-32-GBovo Nordisk A/S100
进行中（未招募）
1 期
iraglutide Effect and Action in Diabetes (LEAD-2): Effect on glycaemic control after once daily administration of liraglutide in combination with metformin versus metformin monotherapy versus metformin and glimepiride combination therapy in subjects with type 2 diabetes. A six-month double-blind, double-dummy, randomised, active control, parallel-group, multi-centre, multi-national trial with an 18 months trial extension periodMedDRA version: 8,0Level: PTClassification code 10012601Diabetes MellitusEUCTR2005-003417-32-SKovo Nordisk A/S1,865